NGM Biopharmaceuticals is a biopharmaceutical company involved in the discovery and development of medicines for various diseases. The company focuses on creating biologic drug candidates to address medical needs and advancing them through clinical trials. NGM Biopharmaceuticals' research and development efforts are directed towards generating medicines that target various market indications. It was founded in 2008 and is based in South San Francisco, California.

Kaperio is a biopharmaceutical company focused on cardiovascular disease.

Timi3 Systems, Inc., a biotechnology company, develops a non-invasive transcutaneous ultrasound system for the treatment of patients experiencing an acute myocardial infarction or heart attack. The company specializes in the non-invasive delivery of thrombolytic drugs that hasten the dissolution of thrombus during a myocardial infarction. Timi3 Systems, Inc. was founded in 1999 and is based in Santa Clara, California.

InsectiGen, Inc. is a biotechnology company focused on discovery and development of biopesticides. Founded by Clifton Baile, PhD and Michael Adang PhD, InsectiGen has licensed IP from the University of Georgia associated with modified proteins form the intestine of insects that enhance natural insecticides produced by Bacillus thuringensis (Bt).

Efficas is a company that provides non-prescription nutraceuticals for asthma management within the medical food industry. Their main product is a blend of Omega Oils and other ingredients aimed at inhibiting leukotriene production, which may help alleviate asthma symptoms for both adults and children. Efficas serves the healthcare sector with a focus on asthma sufferers looking for relief options. It was founded in 2003 and is based in Boulder, Colorado.

REGiMMUNE is a biotechnology company focusing on the development of medicines related to immune system modulation. The company's treatments focus on inducing tolerance or creating an anti-tumor immune response. REGiMMUNE's offerings include therapies that regulate the immune system, particularly through the use of regulatory T cells. It was founded in 2006 and is based in Tokyo, Japan.